Bruce A. Chabner, MD


Chabner with pad

Dr. Bruce Chabner serves as the Clinical Director Emeritus for the Massachusetts General Hospital Cancer Center and a Professor of Medicine at Harvard Medical School.

His main fields of research focus on the biochemistry and pharmacology of folate antagonists, experimental therapeutics, and clinical trial design.

He has served as the Chief of Hematology and Oncology at the MGH from 1995 to 2007, the Clinical Director of the MGH Cancer Center from 1995 to 2010, and Associate Director of Clinical Science at Dana Farber/Harvard Cancer Center (2000-2010). Prior to accepting his position at MGH, he served in the US Public Health Service at the National Institutes of Health from 1971 to 1995 and held the position of Director of the Division of Cancer Treatment of the National Cancer Institute from 1982 to 1995, retiring as an Assistant Surgeon General in 1995.

Dr. Chabner received his B.A., summa cum laude, from Yale College (1961) and an M.D., cum laude, from Harvard Medical School (1965).

He has authored and edited the standard text, Principles and Practice of Cancer Chemotherapy and Biological Response Modifiers, now in its sixth edition, and the Harrison’s Manual of Oncology, now in its 2nd edition. Dr. Chabner has contributed to and served as editor of the Goodman and Gilman textbook of Pharmacology and has authored chapters for numerous other textbooks of internal medicine, hematology, oncology and pharmacology.

Over the years, Dr. Chabner has received awards including Phi Beta Kappa, Alpha Omega Alpha, the Public Health Service's Distinguished Service Medal, the Karnofsky Award of the American Society for Clinical Oncology and the Bruce F. Cain Award for Drug Development of the American Association for Cancer Research. In 2006, he was the first recipient of the Bob Pinedo Award for Contributions to Improvement in the Care of Cancer Patients.

Dr. Chabner is founding editor-in-chief for The Oncologist and serves on the executive advisory boards for some of the industry’s leading innovators in drug development. In 2006, Dr. Chabner received a presidential appointment to the National Cancer Advisory Board at the National Cancer Institute and chaired the NCAB from (2010-2012). In 2020, he was selected to be the Inaugural speaker for the FDA series, “Icons of Oncology”’.

Jayne S. Gurtler, MD, FACP

Director of CME

Dr. Jayne Gurtler is a founding partner of Metairie Oncologist. She is a graduate of Newcomb College, Tulane University, and Tulane University School of Medicine. She completed her Internal Medicine Residency and Hematology/Oncology Fellowship training at Ochsner Foundation Hospital and followed this with a fellowship in Developmental Therapeutics from MD Anderson Hospital and Tumor Institute.

Dr. Gurtler is a Fellow of the American College of Physicians-American Society of Internal Medicine and an active member of the American Society of Clinical Oncology and Jefferson Parish Medical Society.

Dr. Gurtler serves on the editorial board of The Oncologist, a peer-reviewed academic publication of The Society for Translational Oncology.

Dr. Gurtler teaches students at Xavier University School of Pharmacy. She has conducted oncology research for more than 40 years and has over 20 publications in the last ten years. Every day, Dr. Gurtler strives to help her patients live fuller lives.

Ann Murphy, PhD

Ann Murphy, PhD

Ann Murphy, PhD, is publisher and founding editor of three international, peer-reviewed journals: The Oncologist, STEM CELLS, and STEM CELLS Translational Medicine. Ann is also the founding Director General for the Society for Translational Oncology (STO).

Over its 39-year history, Ann has managed STEM CELLS, the oldest journal in the fast-paced area of stem cells and regenerative medicine research. She fosters the Journal’s excellence as it expands its size and scope as a top-tier, global peer-reviewed journal devoted to stem cell biology emphasizing mechanistic studies that have the potential to better understand disease and possible cell-based therapeutics. Ann works closely with editor-in-chief Jan A. Nolta, PhD, Institute of Regenerative Cures, UC Davis.

Over its 26-year history, Ann has guided and nurtured the growth and development of The Oncologist, the official monthly journal of STO dedicated to physicians devoted to cancer patient care. Ann has also led The Oncologist’s Continuing Medical Education (CME) Program from its inception. Ann works closely with The Oncologist’s founding editor-in-chief, Bruce A. Chabner, MD, Massachusetts General Hospital Cancer Center.

Ann is executive editor for STEM CELLS Translational Medicine (SCTM), the official journal partner of the Regenerative Medicine Foundation, the Cord Blood Association and the Regenerative Medicine Manufacturing Society. SCTM, celebrating its 10th year in 2021, bridges stem cell molecular and biological research and helps speed translation of emerging lab discoveries into clinical trials, helping move applications of these critical investigations closer to accepted best patient practices that improve outcomes. Ann works closely with SCTM’s founding editor-in-chief, Anthony Atala, MD, Director, Wake Forest Institute for Regenerative Medicine.

Ann holds a Doctorate of Philosophy with distinction in Literature from New York University. She serves on the Board of Visitors for the UNC Lineberger Comprehensive Cancer Center. She is a published authority on the Irish Literary Renaissance and the biographer of the Irish playwright and poet, Padraic Colum. A mother of five and grandmother of 10, she makes her home with her husband, Martin J. Murphy, in Durham, North Carolina.